your market intelligence analyst
Search Results
127 results
Your search is now limited to «Celgene» expert search.
Business Wire 10/18/2019 06:59
... participation date of May 1, 2019, requisite consents were received and supplemental indentures were executed, eliminating substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes.
More from Business Wire:
FierceMedicalDevices 09/27/2019 08:13
As Celgene gradually phases into parent company Bristol-Myers Squibb, this is leaving little room at the inn for some of the top execs.
More from FierceMedicalDevices:
ENDPOINTS 09/18/2019 11:08
The pharmaceutical industry has been merging like Porsches on the autobahn of late, raising concerns from unions and consumer groups that a growing oligopoly is promoting anti-competitive practices. Now the mergers have provoked the ire of US lawmakers as eight Democratic senators and one wily-haired independent have written a letter to the Federal Trade Commission asking the regulatory agency to crackdown and specifically scrutinize two pending deals: AbbVie’s for Allergan and Bristol-Myers Squibb proposed of Celgene. “The industry consolidation is occurring against a backdrop of ever-rising prescription drug spending and reports that one in four people taking prescription drugs have difficulty affording their medication,” the senators, le.
More from ENDPOINTS:
Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints.
More from Pharmaceutical Business Review:
PMLiVE 09/13/2019 06:10
Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory filings in the first half of 2020.
More from PMLiVE:
Pharmafile 08/29/2019 06:32
Celgene will have the option to assume worldwide commercial and manufacturing responsibility for any of these therapies, though Immatics maintains early stage co-development rights or co-funding rights for selected products developed as part of ...
More from Pharmafile:
PharmaTimes 08/29/2019 06:16
The company said that the “closing of the acquisition is contingent on Bristol-Myers Squibb entering into a consent decree with the Federal Trade Commission in connection with the pending Celgene merger, the closing of the pending merger with Celgene and the satisfaction of other customary closing conditions.
Benzinga 08/28/2019 10:54
What Happened Immatics, a biopharma company developing T-cell redirecting cancer immunotherapies, announced a strategic collaboration and option agreement with Celgene to develop novel adoptive cell therapies targeting multiple cancers.
More from Benzinga:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications